Zdrowie i gospodarka · 29/09/2020

FDA Releases Draft Guidance on Responding to Complete Response Letters for ANDAs

The FDA is releasing a draft guidance to help pharmaceutical companies respond to complete response letters for abbreviated new drug applications (ANDAs) within the required timeframe. The guidance outlines potential actions for applicants and factors the FDA will consider when evaluating extension requests.